CHD Stock Forecast & Price Target

Church & Dwight Co is supported by a resilient portfolio of leading brands in healthy categories, with Arm & Hammer, TheraBreath, Hero, Batiste, OxiClean, and others driving about 70% of annual sales and profits. Its innovation engine appears to be accelerating, with new products contributing about 2% points of incremental sales growth versus 1.0-1.5% historically, while management expects ~3% organic sales growth in 3Q and EPS of $0.89 despite roughly $30 million of cost pressures. The company’s balance sheet and cash generation also create optionality for M&A and buybacks, and its still-low international mix at 18% of sales leaves substantial room to expand beyond the home US market.

Church & Dwight Co is facing a muted downside outlook because its core brands are vulnerable to share erosion from elevated competitive promotional activity, which could keep top-line growth near a ~1.2% CAGR and cap margins around ~19% through 2034. The company also remains exposed to volatile raw and packaging costs, limited margin expansion, and the risk that weaker economic conditions or failed product launches could pressure demand and profits. Its reliance on the U.S. for around 80% of sales and on Walmart for more than 20% of sales further concentrates risk, while acquisition and integration missteps could undermine growth.